Journal
CURRENT OPINION IN VIROLOGY
Volume 39, Issue -, Pages 16-22Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2019.06.006
Keywords
-
Categories
Funding
- Instituto de Salud Carlos III-ISCIII (Spanish Government) - FEDER funds/European Regional Development Fund (ERDF) a way to build Europe [CB16/12/00401, CB06/02/0073]
- Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia [2017SGR1718, 2017SGR1085]
Ask authors/readers for more resources
Since 2006, 115 countries and territories have introduced human papillomavirus (HPV) vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV vaccines. Many countries, mainly high-income and with high screening coverage, are already reporting a visible impact of the HPV vaccine on HPV-related diseases. Others, largely low-income and middle-income countries, are introducing HPV vaccine to control HPV diseases that will undoubtedly generate a similar impact. In this review, we will summarize the compelling evidence of the impact of vaccines in reducing the burden of HPV-related disease. The data support additional efforts to make HPV vaccines widely available to adolescent girls in the countries that bear the vast majority of cervical cancer-related morbidity and mortality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available